2765593-43-7
2765593-43-7
Chemical Structure
Linafexor
Synonym(s): CS-0159
- CAS No.: 2765593-43-7
- Formula:C28H25Cl2FN4O4
- Molecular Weight:571.43
InChIKey: CEEANZUSISGCJL-VQFNDLOPSA-N
SMILES: ClC(C=CC=C1Cl)=C1C2=NOC(C3CC3)=C2CO[C@@H]4C[C@@]5([H])N(C6=CC(F)=C(C7=NOC(N7)=O)C=C6)[C@@](CC5)([H])C4
Biological Activity: Linafexor (CS-0159) is a FXR agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Linafexor | 99.58% | Linafexor (CS-0159) is a FXR agonist and bile acid homeostasis modulator. Linafexor exerts its effects by activating FXR, a regulator of liver function. Linafexor is applicable to research related to primary sclerosing cholangitis (PSC). Linafexor is also suitable for research in the field of metabolic dysfunction-associated steatohepatitis (MASH). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pham HN, et al. Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis. Expert Opin Pharmacother. 2024;25(7):895-906. [Content Brief]
- [2]. Chai SY, et al. Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis. World J Gastroenterol. 2025;31(46):113608. [Content Brief]
